# C. Chouaïd

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/c-chouaid/

## Facts

| Field | Value |
| --- | --- |
| Citations | 18,403 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 58 |
| i10-index | 255 |
| Last Known Institution | Inserm |
| OpenAlex ID | https://openalex.org/A5016370905 |
| ORCID iD | https://orcid.org/0000-0002-4290-5524 |
| Works | 1,021 |

## Researcher papers

- [Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial](https://scholariq.org/papers/durvalumab-plus-platinum-etoposide-versus-platinum-etoposide-in-first-line/)
- [Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial](https://scholariq.org/papers/activity-and-safety-of-nivolumab-an-anti-pd-1-immune-checkpoint-inhibitor-for/)
- [Lung Cancer That Harbors an <i>HER2</i> Mutation: Epidemiologic Characteristics and Therapeutic Perspectives](https://scholariq.org/papers/lung-cancer-that-harbors-an-i-her2-i-mutation-epidemiologic-characteristics-and/)
- [Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study](https://scholariq.org/papers/durvalumab-as-third-line-or-later-treatment-for-advanced-non-small-cell-lung/)
- [Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study](https://scholariq.org/papers/treatment-characteristics-and-real-world-progression-free-survival-in-patients/)
- [Bevacizumab in Patients with Nonsquamous Non–Small Cell Lung Cancer and Asymptomatic, Untreated Brain Metastases (BRAIN): A Nonrandomized, Phase II Study](https://scholariq.org/papers/bevacizumab-in-patients-with-nonsquamous-non-small-cell-lung-cancer-and/)
- [Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial](https://scholariq.org/papers/afatinib-beyond-progression-in-patients-with-non-small-cell-lung-cancer/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Economic and Financial Impacts of Cancer](https://scholariq.org/topics/economic-and-financial-impacts-of-cancer/)

## Researcher university

- [Inserm](https://scholariq.org/institutions/inserm/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.